Social Media Ideas for 340B

The 340B Squeeze: Academic Medical Centers and Large Health Systems Have the Most to Lose

Three federal pricing changes are about to land on a single outpatient claim. The largest infusion and oncology programs will feel them first, and hardest. Most of the 340B debate...

This Week in 340B- August 25 – 31, 2026

This Week in 340B: October 6 – 12, 2026

This Week in 340B: October 13 – 19, 2026

This Week in 340B—September 22 – 28, 2026

<![CDATA[340B Under Pressure: Inside Pharma's Push for Greater Clarity]]>

This Week in 340B: September 8 – 14, 2026

This Week in 340B: August 18 – 24, 2026

This Week in 340B: September 1 – 7, 2026

HHS: 340B 'expanded beyond its original intent,' incentivizes consolidation

A new brief lays out the administration's views and critiques of the controversial hospital subsidy program, and includes a data analysis suggesting that a proposed reimbursement c...

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

340B Rebate Pilot — The Clock Starts Now

HRSA names 10 drugmakers for revised 340B rebate pilot ahead of 2027 launch

The list of approved participants and drugs is larger than the controversial pilot's first attempted launch. It comes the same day that CMS launched a soon-to-be-mandatory data rep...

Drug Channels News Roundup, September 2026: The 340B Margin Squeeze, Economics of Cutting List Price, Patient Adherence...

By Bryce Platt, PharmD Football season is officially back. Personally, my signal is hearing my uncle curse about bad calls from 1,000 miles away, but you may have already seen...

This Week in 340B: September 15 – 21, 2026

Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 3...

Froedtert sues CVS over $18M in 340B drug discounts

Froedtert Hospital is suing CVS Health, alleging CVS improperly kept $18 million in reimbursements from the federal 340B drug discount program. The post Froedtert sues CVS over $18...

This Week in 340B: September 29 – October 5, 2026

Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 3...

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...

The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs (rerun)

The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs (rerun) Anonymous (not verified) Thu, 10/08/2026 - 07:08 pharmagather item url...

Hospital outpatient departments' higher drug reimbursement rates drive $12.7B in spending: EBRI

An analysis of commercial claims for 106 physician-administered outpatient drugs suggests $101 of additional plan spending per member per year stemming from site-of-treatment pay d...

CD&R, McKesson acquiring infusion therapy provider Option Care Health for $5.8B

Option Care Health, the country's largest independent provider of at-home and alternate site infusion services, would go private in the deal, which is expected to close in the firs...

White House to dispense Part B rebates to more than 20M enrollees

On the heels of news that the White House would offer rebates to nearly 1 million people enrolled in Affordable Care Act plans, the Trump administration said Monday that it will pa...

HHS-OIG Issues Favorable Advisory Opinion Regarding Independent Charity Patient Assistance Program

<![CDATA[Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million ]]>